Compare Corning Incorporated (GLW) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? Corning Incorporated trades at $156.69 (market cap $131.65B), while State Street SPDR S&P Biotech ETF trades at $153.77 (market cap $10.11B). The key difference: Corning Incorporated is far larger — about 13× State Street SPDR S&P Biotech ETF's market cap, and Corning Incorporated pays a 0.73% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| GLW | XBI | |
|---|---|---|
Market Cap | $131.65B | $10.11B |
Volume | 8,992,522 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $255.79 | $169.55 |
52-Week Low | $78.03 | $104.99 |
Typical Hold Time | 36 Days | 38 Days |
Enterprise Value | $138.52B | — |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $155.95, down 4.45% today amid a bearish technical outlook despite strong fundamentals. The company recently secured a significant $3B+ fiber supply agreement with AT&T, boosting its optical communications segment. GLW has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Analyst consensus remains positive with a $171.25 price target, though technical indicators show selling pressure with support at $149 and resistance at $158.
GLW presents a compelling long-term opportunity with strong revenue growth projections and strategic positioning in fiber optics for AI infrastructure. However, elevated valuation multiples (P/E 70.43) and ongoing patent litigation investigations pose near-term risks. The stock's current technical weakness may offer entry points for investors bullish on the company's fiber optic expansion and AI-driven connectivity demand.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
